Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
Globe Newswire (Wed, 22-Jul 6:00 AM ET)
Globe Newswire (Mon, 11-May 9:17 AM ET)
Biodesix Raises Full-Year Revenue Outlook on 42% Q1 Sales Growth and Improving Margins
Market Chameleon (Tue, 5-May 4:55 AM ET)
Biodesix Announces First Quarter 2026 Results and Highlights
Globe Newswire (Mon, 4-May 4:01 PM ET)
Biodesix Surpasses Revenue Guidance and Affirms Positive Adjusted EBITDA for Q4 2025
Market Chameleon (Mon, 12-Jan 2:05 AM ET)
Biodesix Spotlights Advances in Lung and Breast Cancer Diagnostics at Two Major Conferences
Market Chameleon (Thu, 4-Dec 6:20 AM ET)
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Biodesix trades on the NASDAQ stock market under the symbol BDSX.
As of July 22, 2026, BDSX stock price climbed to $21.39 with 87,992 million shares trading.
BDSX has a beta of 0.53, meaning it tends to be less sensitive to market movements. BDSX has a correlation of 0.00 to the broad based SPY ETF.
BDSX has a market cap of $221.51 million. This is considered a Small Cap stock.
Last quarter Biodesix reported $26 million in Revenue and -$.81 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.32.
In the last 3 years, BDSX traded as high as $44.20 and as low as $3.44.
The top ETF exchange traded funds that BDSX belongs to (by Net Assets): VTI, VXF, IWC.
BDSX has outperformed the market in the last year with a price return of +205.6% while the SPY ETF gained +20.1%. BDSX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +66.5% and +5.2%, respectively, while the SPY returned +6.4% and 0.0%, respectively.
BDSX support price is $19.61 and resistance is $22.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDSX shares will trade within this expected range on the day.